title: [Pharmaceutical therapy of bone metabolism disorders in chronic kidney disease mineral bone disorder (CKD-MBD) with special respect to antiresorptive substances].
abstract: Disturbances in bone and mineral turnover are common complications in patients with impaired renal function. Besides an increased risk for cardiovascular events they promote skeletal events, such as bone pain and fractures. Evidence for the antifracture efficacy of antiresorptive and osteoanabolic treatment strategies has only been demonstrated for patients with osteoporosis. The use of osteotropic drugs in patients with impaired renal function requires large randomized placebo-controlled trials.
authors.affiliation: Klinik Innere Medizin III, Rheumatologie/Osteologie, Universitätsklinikum Jena, Erlanger Allee 101, 07740, Jena, Deutschland, Gabriele.Lehmann@med.uni-jena.de.
authors.forename: G
authors.initials: G
authors.lastname: Lehmann
authors.forename: G
authors.initials: G
authors.lastname: Wolf
mesh_terms: D015519:Bone Density / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001842:Bone and Bones / Q000473:pathology; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D000089703:Fibroblast Growth Factor-23; D005346:Fibroblast Growth Factors / Q000097:blood; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy / Q000209:etiology / Q000473:pathology; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology; D010024:Osteoporosis / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D016032:Randomized Controlled Trials as Topic; D006435:Renal Dialysis / Q000009:adverse effects; D012307:Risk Factors
chemical_list: D050071:Bone Density Conservation Agents; D005346:Fibroblast Growth Factors; D000089703:Fibroblast Growth Factor-23